Skip to content

Study · Randomized controlled trial · n = 47 · 2009

11 results

[Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial].

Zhou LX, Tan JJ, Li YN, Luo HT, Shao YH, Qiang XH, Yu TO, Ma MY, Mao KJ, Fang B

Zhonghua yi xue za zhi1 Apr 2009Cited by 6 (Europe PMC)

PMID19595251 (opens in a new tab)PepBankPUB-19595251
Publisher pageAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, CD3+ T lymphocytes on day 8 were significantly higher with thymosin alpha1 than with standard therapy only.

    In plain wordsIn adults with severe sepsis, thymosin alpha1 gave higher CD3+ T cell counts on day 8 than standard care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3+ T lymphocytes on day 8 versus SSC
    Study

    n = 47

    Comparator
    SSC Group (standard therapy only)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The CD(3)(+) T lymphocyte number on day 8 of Thymosin Group was significantly higher than that of SSC Group (all P < 0.05).
    1 context sentence
    Summary · context
    Thymosin alpha(1) Group (n = 23) undergoing subcutaneous injection of thymosin alpha(1) 1.6 mg once a day for 7 days
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, ventilation time, ICU stay and 28- and 90-day mortality were lower than with standard therapy only in all three treatment groups, but the abstract reports significant differences only for the CBP and combined groups, not for the thymosin group.

    In plain wordsIn adults with severe sepsis, ventilation time, ICU stay and deaths were lower with thymosin alpha1 than standard care, but not reported as significant.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeVentilation time, ICU stay and mortality versus SSC
    Study

    n = 47

    Comparator
    SSC Group (standard therapy only)
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    1.6 mg · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with those of SSC Group, the mechanical ventilation time, length of ICU stay within 28 days, and 28 days mortality and 90 days mortality of the 3 treatment groups were all decreased, and there were statistical differences in the length of ICU stay of CBP Group and in the mechanical ventilat…
    1 context sentence
    Summary · context
    Thymosin alpha(1) Group (n = 23) undergoing subcutaneous injection of thymosin alpha(1) 1.6 mg once a day for 7 days

Studies that did not test the peptide alone9

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 shortened mechanical ventilation time within 28 days versus standard therapy only.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 shortened ventilator time compared with standard care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMechanical ventilation time within 28 days, combined therapy versus SSC
    Study

    n = 46

    Comparator
    SSC Group (standard therapy only)
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    there were statistical differences in the length of ICU stay of CBP Group and in the mechanical ventilation time and length of ICU stay within 28 days of Combined Therapy Group (both P < 0.05).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 shortened ICU stay within 28 days versus standard therapy only.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 shortened ICU stay compared with standard care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseICU stay within 28 days, combined therapy versus SSC
    Study

    n = 46

    Comparator
    SSC Group (standard therapy only)
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    there were statistical differences in the length of ICU stay of CBP Group and in the mechanical ventilation time and length of ICU stay within 28 days of Combined Therapy Group (both P < 0.05).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 raised CD3+ T lymphocytes on day 4 more than thymosin alpha1 alone.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 raised CD3+ T cells on day 4 more than thymosin alpha1 alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3+ T lymphocytes on day 4, combined therapy versus thymosin alone
    Study

    n = 45

    Comparator
    Thymosin alpha1 group
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    only the CD(3)(+) T lymphocyte level on day 4 increased and the IL-6/IL-10 ratio on day 8 was decreased significantly in Combined Therapy Group (both P < 0.05).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 lowered the IL-6/IL-10 ratio on day 8 more than thymosin alpha1 alone.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 lowered the IL-6/IL-10 ratio on day 8 more than thymosin alpha1 alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6/IL-10 ratio on day 8, combined therapy versus thymosin alone
    Study

    n = 45

    Comparator
    Thymosin alpha1 group
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    only the CD(3)(+) T lymphocyte level on day 4 increased and the IL-6/IL-10 ratio on day 8 was decreased significantly in Combined Therapy Group (both P < 0.05).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 07HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 lowered TNF-alpha on day 4.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 lowered TNF-alpha on day 4.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTNF-alpha on day 4, combined therapy
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    The level of TNFalpha decreased, and the numbers of CD(3)(+) and CD(4)(+) T lymphocytes increased significantly on day 4 in Combined Therapy Group (P < 0.05 or P < 0.01).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 08HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 raised CD3+ T lymphocytes on day 4.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 raised CD3+ T cells on day 4.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3+ T lymphocytes on day 4, combined therapy
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The level of TNFalpha decreased, and the numbers of CD(3)(+) and CD(4)(+) T lymphocytes increased significantly on day 4 in Combined Therapy Group (P < 0.05 or P < 0.01).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 09HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, combined CBP plus thymosin alpha1 raised CD4+ T lymphocytes on day 4.

    In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 raised CD4+ T cells on day 4.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T lymphocytes on day 4, combined therapy
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The level of TNFalpha decreased, and the numbers of CD(3)(+) and CD(4)(+) T lymphocytes increased significantly on day 4 in Combined Therapy Group (P < 0.05 or P < 0.01).
    1 context sentence
    Summary · context
    Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 10HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, serum IL-6, TNF-alpha and the IL-6/IL-10 ratio were significantly decreased on day 8 in the CBP and combined CBP plus thymosin alpha1 groups.

    In plain wordsIn adults with severe sepsis, blood purification alone and blood purification plus thymosin alpha1 lowered IL-6, TNF-alpha and the IL-6/IL-10 ratio on day 8.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6, TNF-alpha and IL-6/IL-10 ratio on day 8, CBP and combined therapy
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    The serum IL-6 and TNFalpha and IL-6/IL-10 were decreased, and HLA-DR, and CD(3)(+), CD(4)(+), and CD(8)(+) were increased significantly on day 8 in CBP and Combined Therapy Groups.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 11HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with severe sepsis, HLA-DR and CD3+, CD4+ and CD8+ T lymphocytes were significantly increased on day 8 in the CBP and combined CBP plus thymosin alpha1 groups.

    In plain wordsIn adults with severe sepsis, blood purification alone and blood purification plus thymosin alpha1 raised HLA-DR and T cell counts on day 8.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHLA-DR and CD3+, CD4+, CD8+ T lymphocytes on day 8, CBP and combined therapy
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The serum IL-6 and TNFalpha and IL-6/IL-10 were decreased, and HLA-DR, and CD(3)(+), CD(4)(+), and CD(8)(+) were increased significantly on day 8 in CBP and Combined Therapy Groups.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.